“No cure for the common cold?”; two years socially distanced, our exposure to Rhinovirus, the primary cause of the common cold is low and as the impact of the Covid-19 pandemic reduces, we will again be challenged by circulating viruses, typically responsible for 26.1Million UK sick days (ONS, 2021). Patent pending with in-vitro proof of concept demonstrated against Rhinovirus, PlusPEP®, promises to be Scotland’s first “antiviral, immunity boosting pill”.

Exported globally, selling direct online or through pharmacies and supermarkets, future Napier spinout PlusPEP Ltd aims a first product launch into the $29Bn global immune health supplements market in 2025.